Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative effectiveness of second-line therapies for chronic immune thrombocytopenia: A network meta-analysis of RCTs

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAnusha KalluruInstitute of Medical SciencesHRHarshawardhan Dhanraj RamtekeHeart Rhythm SocietySNShanthi NarlaMedical College of Wisconsin

Discussion

Loading...

Member takes

Overview

Network meta-analysis reveals second-line therapies improve quality of life in chronic immune thrombocytopenia patients, highlighting risk of adverse events.

Key Points

  • This analysis aims to evaluate the comparative effectiveness of second-line therapies for chronic immune thrombocytopenia (ITP).
  • Conducted a systematic search of five databases for RCTs related to ITP.
  • Performed a network meta-analysis using the Netmeta package in R.
  • Assessed the quality and risk of bias of studies using the ROB 2.0 tool.
  • Included 17 studies with 3321 patients for analysis.
  • Rozanolixizumab identified as the most effective second-line therapy for chronic ITP.
  • Overall survival odds ratios calculated for therapies, with specific OR values provided for each.
  • Quality of life, measured by ITP-QOL, increased by approximately 16 points across treatments.
  • The analysis indicated variability in safety profiles among the therapies.

Cite This Study

Kalluru et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbc7https://doi.org/10.1182/blood-2025-6592
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of non-first-line drugs in the treatment of immune thrombocytopenia: a systematic review and network meta-analysis2025 · 1 citations
  2. 2The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial2025
  3. 3Rituximab beats the odds in ITP? a 5-year national showdown against TPO-ras2025
  4. 4Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia2024
  5. 5Effectiveness and Safety of Two Thrombopoietin Receptor Agonists: A Retrospective Cohort Study of Adults With Primary Immune Thrombocytopenia2026